Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Study of BIIB092 in Participants With Progressive Supranuclear Palsy

ClinicalTrials.gov ID: NCT03068468

Public ClinicalTrials.gov record NCT03068468. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear Palsy

Study identification

NCT ID
NCT03068468
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Biogen
Industry
Enrollment
490 participants

Conditions and interventions

Interventions

  • BIIB092 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
41 Years to 86 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2017
Primary completion
Sep 5, 2019
Completion
Feb 6, 2020
Last update posted
Dec 20, 2020

2017 – 2020

United States locations

U.S. sites
33
U.S. states
18
U.S. cities
28
Facility City State ZIP Site status
Research Site Phoenix Arizona 85013
Research Site Scottsdale Arizona 85259
Research Site Sun City Arizona 85351
Research Site Fountain Valley California 92708
Research Site La Jolla California 92037
Research Site Los Angeles California 90095
Research Site San Francisco California 94158
Research Site Boca Raton Florida 33486
Research Site Gainesville Florida 32607
Research Site Tampa Florida 33612-4742
Research Site Chicago Illinois 60611
Research Name Chicago Illinois 60612-3841
Research Site Chicago Illinois 60637-1447
Research Site Indianapolis Indiana 46202-2280
Research Site Kansas City Kansas 66160
Research Site New Orleans Louisiana 70121-2429
Research Site Baltimore Maryland 21201
Research Site Baltimore Maryland 21287
Research Site Boston Massachusetts 02114
Research Site Burlington Massachusetts 01702
Research Site Farmington Hills Michigan 48334
Research Site Minneapolis Minnesota 55455-0341
Research Site New Brunswick New Jersey 08901
Research Site Albany New York 12208
Research Site New York New York 100029
Research Site New York New York 10029
Research Site New York New York 10032-3725
Research Site Hershey Pennsylvania 17033
Research Site Philadelphia Pennsylvania 19104
Research Site Charleston South Carolina 29425
Research Site Dallas Texas 75390-8869
Research Site Charlottesville Virginia 22908-0394
Research Site Seattle Washington 98122

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03068468, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 20, 2020 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03068468 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →